AR009560A1 - Prolongacion de la sobrevida de injertos con porfirinas - Google Patents

Prolongacion de la sobrevida de injertos con porfirinas

Info

Publication number
AR009560A1
AR009560A1 ARP970104091A ARP970104091A AR009560A1 AR 009560 A1 AR009560 A1 AR 009560A1 AR P970104091 A ARP970104091 A AR P970104091A AR P970104091 A ARP970104091 A AR P970104091A AR 009560 A1 AR009560 A1 AR 009560A1
Authority
AR
Argentina
Prior art keywords
survival
porphyrins
prolongation
graft
metalloporphyrins
Prior art date
Application number
ARP970104091A
Other languages
English (en)
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of AR009560A1 publication Critical patent/AR009560A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dentistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se administran metaloporfirinas junto con el transplante para aumentar la sobrevida del organo.
ARP970104091A 1996-09-09 1997-09-08 Prolongacion de la sobrevida de injertos con porfirinas AR009560A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/709,650 US5756492A (en) 1996-09-09 1996-09-09 Graft survival prolongation with porphyrins

Publications (1)

Publication Number Publication Date
AR009560A1 true AR009560A1 (es) 2000-04-26

Family

ID=24850771

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104091A AR009560A1 (es) 1996-09-09 1997-09-08 Prolongacion de la sobrevida de injertos con porfirinas

Country Status (8)

Country Link
US (2) US5756492A (es)
EP (1) EP0865275A2 (es)
JP (1) JP3287851B2 (es)
AR (1) AR009560A1 (es)
AU (1) AU740531B2 (es)
CA (1) CA2234886A1 (es)
WO (1) WO1998009618A2 (es)
ZA (1) ZA977960B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
JP2003500335A (ja) * 1998-12-17 2003-01-07 サングスタット メディカル コーポレイション ヘムオキシゲナーゼ活性の調節による移植片の生存を強化する方法
EP1616869B1 (en) 1999-01-25 2012-04-04 National Jewish Health Substituted porphyrins and their therapeutic use
WO2000046183A1 (en) 1999-02-08 2000-08-10 Checkpoint Genetics, Inc. N-substituted amino acids, antioxidant pharmaceutical compositions containing same and methods using same
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
CA2436245C (en) 2001-01-19 2013-04-23 National Jewish Medical And Research Center Medicament for protection in radiotherapy
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1439842A4 (en) * 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
AU2002358158A1 (en) * 2001-12-19 2003-06-30 D. Collen Research Foundation Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
CN1646140A (zh) * 2002-02-04 2005-07-27 阿尔法玛药品研发有限公司 可释放co的化合物在用于治疗炎症药物的制备中的应用
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20040143025A1 (en) * 2002-04-01 2004-07-22 Roland Buelow Carbon monoxide generating compunds for treatment of vascular, inflammatory and immune disorders
JP2005522521A (ja) * 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
US7485721B2 (en) * 2002-06-07 2009-02-03 Duke University Substituted porphyrins
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
JPWO2006054757A1 (ja) * 2004-11-16 2008-06-05 アステラス製薬株式会社 カスパーゼ阻害剤
EP1762248A1 (en) * 2005-09-09 2007-03-14 CORIT Consorzio per la Ricerca sul Use of cobalt porphyrins in joint therapy with an immunosuppressant drug for treatment of transplant patients or autoimmune disorders
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US11382895B2 (en) 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
WO2012145520A2 (en) 2011-04-19 2012-10-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
EP2767278B1 (en) 2011-10-12 2019-11-06 SBI Pharmaceuticals Co., Ltd. Enhancer of survival of transplanted organ
JP5904518B2 (ja) 2012-07-13 2016-04-13 Ｓｂｉファーマ株式会社 免疫寛容誘導剤
WO2018144845A1 (en) * 2017-02-03 2018-08-09 The Board Of Trustees Of The Leland Stanford Junior University Metalloporphyrin microparticles for treatment of anemia and tropical diseases
EP4370137A1 (en) * 2021-07-12 2024-05-22 Renibus Therapeutics, Inc. Metal protoporphyrin for treatment of bk virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829984A (en) * 1983-12-15 1989-05-16 Gordon Robert T Method for the improvement of transplantation techniques and for the preservation of tissue
US5563132A (en) * 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
CA2132690A1 (en) * 1994-09-22 1996-03-23 Dean Willis Control and modulation of inflammatory response in humans in need of such control and modulation

Also Published As

Publication number Publication date
JP3287851B2 (ja) 2002-06-04
WO1998009618A2 (en) 1998-03-12
AU4734497A (en) 1998-03-26
WO1998009618A3 (en) 1998-05-07
EP0865275A2 (en) 1998-09-23
ZA977960B (en) 1998-03-02
AU740531B2 (en) 2001-11-08
US5756492A (en) 1998-05-26
US6060467A (en) 2000-05-09
JPH11507083A (ja) 1999-06-22
CA2234886A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
AR009560A1 (es) Prolongacion de la sobrevida de injertos con porfirinas
DK0907652T3 (da) Immunosuppressive forbindelser og fremgangsmåder
ES2175460T3 (es) Compuesto de lipoxinas y su utilizacion en el tratamiento de patologias con proliferacion celular.
EA200100369A1 (ru) Химиотерапия рака с помощью ацетилдиналина в комбинации с гемцитабином, кэйпцитабином или цис-платиной
MX9200675A (es) Derivados de 2,4-diaminoquinazolinas para mejorar la actividad antitumoral.
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
ES2093694T3 (es) Nuevos derivados de dihidro-isoquinoleina.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2061587T3 (es) Compuestos aromaticos y heteroaromaticos alfa,alfa-disustituidos como mejoradores de la cognicion.
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
EP0809437A4 (en) THIOLS USED TO PROMOTE THE GROWTH OF PARENT HEMATOPOIETIC CELLS
ES2061586T3 (es) Analogos disulfuricos de agentes antitumorales ll-e33288.
ES2166900T3 (es) Derivados de ara-c.
ES2187799T3 (es) Complejos de bis-platino con derivados de polimetileno como ligandos que tienen actividad antitumoral.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
ATE172115T1 (de) Parenterale lösungen enthaltend 3- dialkylaminoethoxybenzoylbenzofurane
IL131478A0 (en) Methods for treatment of scar tissue
ES2105959B1 (es) Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
DE69835210D1 (de) Verwendung von hyaluronidase zur herstellung eines arzneimittels zur behandlung von entzündungen

Legal Events

Date Code Title Description
FB Suspension of granting procedure